Detalhe da pesquisa
1.
Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN-003/MYX.1 single arm phase II trial.
Am J Hematol
; 96(5): 552-560, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33650179
2.
Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression.
Exp Cell Res
; 316(19): 3197-206, 2010 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20736003
3.
A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia.
Clin Lymphoma Myeloma Leuk
; 21(11): 766-774, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34334330
4.
Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial.
JAMA Oncol
; 6(11): 1751-1758, 2020 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32940628
5.
Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome.
Eur J Cancer
; 51(17): 2501-7, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26338195
6.
Activated macrophages inhibit human cytotrophoblast invasiveness in vitro.
Biol Reprod
; 73(2): 237-43, 2005 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-15800179